Tirzepatide

Also known as: Mounjaro, Zepbound, dual GIP/GLP-1 agonist

Evidence Tier Amedium riskintermediaterx approved

Dual GIP/GLP-1 agonist with strong FDA-approved human data for glycemic control and weight loss.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

Overview

Tirzepatide is a dual incretin agonist targeting both GLP-1 and GIP receptors. Clinical data show strong weight-loss and glycemic outcomes, often exceeding semaglutide in comparative datasets. Main caveat: unofficial or compounded sourcing carries the same quality and dosing concerns FDA has highlighted for this class.

Research Details

Mechanism of Action

Dual GIP and GLP-1 receptor agonism increases insulin secretion, reduces glucagon, suppresses appetite, and improves metabolic control.

Study Dose Range

Approved human use: 2.5 mg to 15 mg weekly subcutaneous with titration.

Administration Routes

subcutaneous

Onset / Timeline

Metabolic effects begin within weeks; major body-composition changes accrue over months.

Expected Effects

Large reductions in HbA1c and body weight in approved-use populations, with reduced appetite and improved metabolic markers.

Adverse Effects

GI intolerance is most common: nausea, vomiting, diarrhea, constipation, and appetite suppression. Gallbladder and pancreatitis concerns remain relevant.

Contraindications

Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, pregnancy, and other glucose-lowering drugs.

Interaction Notes

Additive hypoglycemia risk with insulin or secretagogues. Delayed gastric emptying can affect oral-drug absorption timing.

Related Goals

Fat Loss & Metabolism

Known Interactions

contraindicated with Semaglutide

Do not layer GLP-1 / dual-incretin agonists in a consumer stack; GI burden and dosing complexity rise without a clear rationale.

contraindicated with Liraglutide

Dual incretin and GLP-1-only agonists should not be stacked in consumer protocols.

contraindicated with Retatrutide

Two high-potency incretin agonists compound GI and glucose-management risk.

Available From

No vendors currently listed for this peptide.

Read this before you compare products

RUO vs Human Use

How to think about research-use-only products, approved drugs, and why RUO language does not make a listing trustworthy by itself.

Read guide

FDA & Regulatory Basics

A practical guide to the regulatory language users keep seeing—approved drugs, compounding risk, RUO listings, and why that context changes how products should be presented.

Read guide

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.